Biopharmaceuticals: Post-Translational Modification Carboxylation and Hydroxylation

Post-translational Modification of Protein Biopharmaceuticals

Volumn , Issue , 2009, Pages 209-252

  Brown, Mark A ^a,b   Stenberg, Leisa M ^a,b  

^a MARINE BIOLOGICAL LABORATORY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biopharmaceuticals; Ca2+ binding; Carboxylation; Conotoxins; Hydroxylation

Indexed keywords

EID: 78649919102     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626601.ch9     Document Type: Chapter

References (303)

1. Aledort, L.M. (1999) Economic aspects of haemophilia care in the United States. Haemophilia, 5, 282-285.
2. Furie, B., Bouchard, B.A. and Furie, B.C. (1999) Vitamin K-dependent biosynthesis of g-carboxyglutamic acid. Blood, 93, 1798-1808.
3. Stafford, D.W. (2005) The vitamin K cycle. Journal of Thrombosis and Haemostasis, 3, 1873-1878.
4. Stenberg, L.M., Brown, M.A. and Stenflo, J. (2002) g-Carboxyglutamic acid (Gla) domains, in Encyclopedia of Molecular Medicine (ed. T. Creighton), John Wiley & Sons, Inc, New York, pp. 1367-1370.
5. Stenflo, J. and Dahlbäck, B. (2001) Vitamin K-dependent proteins in blood coagulation, in The Molecular Basis of Blood Diseases (eds G. Stamatoyannopoulos, P.W. Majerus, R.M. Perlmutter and H. Varmus), W.B. Saunders Co, Philadelphia, PA, pp. 579-613.
6. Murshed, M. et al. (2004) Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins. The Journal of Cell Biology, 165, 625-630.
7. Price, P.A., Faus, S.A. and Williamson, M.K. (1998) Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 1400-1407.
8. Brown, M.A., Stenberg, L.M. and Stenflo, J. (2004) Coagulation factor X, in Handbook of Proteolytic Enzymes (eds A.J. Barrett, N.D. Rawlings and J.F. Woessner), Elsevier Ltd., London, pp. 1662-1666.
9. Nelsestuen, G.L., Zytokovicz, T.H. and Howard, J.B. (1974) Mode of action of vitamin K: identification of g-carboxyglutamic acid as a component of prothrombin. The Journal of Biological Chemistry, 249, 6347-6350.
10. Stenflo, J. et al. (1974) Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proceedings of the National Academy of Sciences of the United States of America, 71, 2730-2733.
11. Stenflo, J. and Ganrot, P.-O. (1972) Vitamin K and the biosynthesis of prothrombin. I. Identification and purification of a dicoumarol-induced abnormal prothrombin from bovine plasma. The Journal of Biological Chemistry, 247, 8160-8166.
12. Stenflo, J. (1972) Vitamin K and the biosynthesis of prothrombin. II. Structural comparison of normal and dicoumarol-induced bovine prothrombin. The Journal of Biological Chemistry, 247, 8167-8175.
13. Stenflo, J. (1973) Vitamin K and the biosynthesis of prothrombin. III. Structural comparison of an NH2- terminal fragment from normal and from dicoumarol-induced bovine prothrombin. The Journal of Biological Chemistry, 248, 6325-6332.
14. Stenflo, J. and Ganrot, P.-O. (1973) Binding of Ca2{thorn} to normal and dicoumarol-induced prothrombin. Biochemical and Biophysical Research Communications, 50, 98-104.
15. Stenflo, J. (1974) Vitamin K and the biosynthesis of prothrombin. IV. Isolation of peptides containing prosthetic groups from normal prothrombin and the corresponding peptides from dicoumarol-induced prothrombin. The Journal of Biological Chemistry, 249, 5527-5535.
16. Fernlund, P. et al. (1975) Vitamin K and the biosynthesis of prothrombin. V. g-Carboxyglutamic acids, the vitamin K-dependent structures in prothrombin. The Journal of Biological Chemistry, 250, 6125-6133.
17. Nelsestuen, G.L. and Suttie, J.W. (1972) Mode of action of vitamin K: calcium binding properties of bovine prothrombin. Biochemistry, 11, 4961-4964.
18. Nelsestuen, G.L. and Suttie, J.W. (1972) The purification and properties of an abnormal prothrombin protein produced by dicumarol-treated cows:a comparison to normal prothrombin. The Journal of Biological Chemistry, 247, 8176-8182.
19. Magnusson, S. et al. (1974) Primary structure of the vitamin K-dependent part of prothrombin. FEBS Letters, 44, 189-193.
20. Roth, D.A. et al. (2001) Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood, 98, 3600-3606.
21. Shapiro, A.D. et al. (2005) The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood, 105, 518-525.
22. Hedner, U. (2001) Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Seminars in Hematology, 38, 43-47.
23. Esmon, C.T. (2002) Protein C pathway in sepsis. Annals of Medicine, 34, 598-605.
24. Furie, B. and Furie, B.C. (2000) Molecular basis of blood coagulation, inHematology:Basic Principles and Practice (eds R. Hoffman, E.J.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein and P. McGlave), Churchill Livingstone, New York, pp. 1783-1804.
25. Manfioletti, G. et al. (1993) The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Molecular and Cellular Biology, 13, 4976-4985.
26. Kulman, J.D. et al. (1997) Primary structure and tissue distribution of two novel proline-rich g-carboxyglutamic acid proteins. Proceedings of the National Academy of Sciences of the United States of America, 94, 9058-9062.
27. Kulman, J.D. et al. (2001) Identification of two novel transmembrane g-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proceedings of the National Academy of Sciences of the United States of America, 98, 1370-1375.
28. Price, P.A., Poser, J.W. and Raman, N. (1976) Primary structure of the g-carboxyglutamic acid-containing protein from bovine bone. Proceedings of the National Academy of Sciences of the United States of America, 73, 3374-3375.
29. Price, J.A. et al. (1980) Structure and function of the vitamin K-dependent protein of bone, in Vitamin K Metabolism and Vitamin K-dependent Proteins (ed J.W. Suttie), University Park Press, Baltimore,Maryland, pp. 219-226.
30. Laizè, V. et al. (2005) Evolution of matrix and bone g-carboxyglutamic acid proteins in vertebrates. The Journal of Biological Chemistry, 280, 26659-26668.
31. Brown, M.A. and Stenflo, J. (2004) Gla-domain, in Handbook of Metalloproteins (eds A. Messerschmidt, W. Bode and M. Cygler), John Wiley & Sons, Ltd., Chichester, England, pp. 573-583.
32. Hauschka, P.V. and Carr, S.A. (1982) Calcium-dependent a-helical structure in osteocalcin. Biochemistry, 21, 2538-2547.
33. Stenflo, J. (1999) Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Critical Reviews in Eukaryotic Gene Expression, 9, 59-88.
34. Stenflo, J. and Dahlbäck, B. (1994) Vitamin K-dependent proteins, in The Molecular Basis of Blood Diseases (eds G. Stamatoyannopoulos, A.W. Nienhuis, P.W. Majerus and H. Varmus), W.B. Saunders Co., Philadelphia, pp. 565-598.
35. Bolt, G., Steenstrup, T.D. and Kristensen, C. (2007) All posttranslational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII. Thrombosis and Haemostasis, 98, 988-997.
36. Brown, M.A. et al. (2005) Precursors of novel Gla-containing conotoxins contain a carboxy-terminal recognition site that directs g-carboxylation. Biochemistry, 44, 9150-9159.
37. Fainzilber, M. et al. (1998) g-Conotoxin-PnVIIA, a g-carboxyglutamate-containing peptide agonist of neuronal pacemaker cation currents. Biochemistry, 37, 1470-1477.
38. Hansson, K. et al. (2004) The first g-carboxyglutamic acid-containing contryphan: a selective L-type calcium ion channel blocker isolated from the venom of Conus marmoreus. The Journal of Biological Chemistry, 279, 32453-32463.
39. McIntosh, J.M. et al. (1984) g-Carboxyglutamate in a neuroactive toxin. The Journal of Biological Chemistry, 259, 14343-14346.
40. Olivera, B.M. et al. (1990) Diversity of Conus neuropeptides. Science, 249, 257-263.
41. Rigby, A.C. et al. (1999) A conotoxin from Conus textile with unusual posttranslational modifications reduces presynaptic Ca2{thorn} influx. Proceedings of the National Academy of Sciences of the United States of America, 96, 5758-5763.
42. Chen, Z. et al. (1998) Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis. The Journal of Biological Chemistry, 273, 16248-16258.
43. Grant, M.A. et al. (2004) The metal-free and calcium-bound structures of a g-carboxyglutamic acid-containing contryphan from Conus marmoreus, Glacontryphan-M. The Journal of Biological Chemistry, 279, 32464-32473.
44. Zhou, L.M. et al. (1996) Synthetic analogues of conantokin-G: NMDA antagonists acting through a novel polyamine-coupled site. Journal of Neurochemistry, 66, 620-628.
45. Bulaj, G. et al. (2003) Efficient oxidative folding of conotoxins and the radiation of venomous cone snails. Proceedings of the National Academy of Sciences of the United States of America, 100, 14562-14568.
46. Hansson, K. et al. (2006) A single g-carboxyglutamic acid residue in a novel cysteine-rich secretory protein without propeptide. Biochemistry, 45, 12828-12839.
47. Bandyopadhyay, P.K. et al. (2002) g-Glutamyl carboxylation: an extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates. Proceedings of the National Academy of Sciences of the United States of America, 99, 1264-1269.
48. Begley, G.S. et al. (2000) A conserved motif within the vitamin K-dependent carboxylase gene is widely distributed across animal phyla. The Journal of Biological Chemistry, 275, 36245-36249.
49. Czerwiec, E. et al. (2002) Expression and characterization of recombinant vitamin K-dependent g-glutamyl carboxylase from an invertebrate, Conus textile. European Journal of Biochemistry, 269, 6162-6172.
50. Goodstadt, L. and Ponting, C.P. (2004) Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends in Biochemical Sciences, 29, 289-292.
51. Li, T. et al. (2000) Identification of a Drosophila vitamin K-dependent g-glutamyl carboxylase. The Journal of Biological Chemistry, 275, 18291-18296.
52. Li, T. et al. (2004) Identification of the gene for vitamin K epoxide reductase. Nature, 427, 541-544.
53. Rost, S. et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 427, 537-541.
54. Walker, C.S. et al. (2001) On a potential global role for vitamin K-dependent g-carboxylation in animal systems:evidence for a g-glutamyl carboxylase in Drosophila. The Journal of Biological Chemistry, 276, 7769-7774.
55. Kulman, J.D. et al. (2006) Vitamin K-dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade. Proceedings of the National Academy of Sciences of the United States of America, 103, 15794-15799.
56. Wang, C.-P. et al. (2003) Identification of a gene encoding a typical g-arboxyglutamic acid domain in the tunicate Halocynthia roretzi. Journal of Thrombosis and Haemostasis, 1, 118-123.
57. MacGillivray, R.T.A. et al. (1993) Structure of the genes encoding proteins involved in blood clotting, in Genetic Engineering:Principles and Methods (ed J.K. Setlow), Plenum Press, New York, pp. 265-330.
58. Wojcik, E.G. et al. (1996) Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with a1-microglobulin. Thrombosis and Haemostasis, 75, 70-75.
59. Gillis, S. et al. (1997) g-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Science, 6, 185-196.
60. Larson, P.J. et al. (1998) Structure/ function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry, 37, 5029-5038.
61. White, G.C. II., Beebe, A. and Nielsen, B. (1997) Recombinant factor IX. Thrombosis and Haemostasis, 78, 261-265.
62. Zhang, L., Jhingan, A. and Castellino, F.J. (1992) Role of individual g-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood, 80, 942-952.
63. Freedman, S.J. et al. (1995) Structure of the calcium ion-bound g-carboxyglutamic acid-rich domain of factor IX. Biochemistry, 34, 12126-12137.
64. Freedman, S.J. et al. (1995) Structure of the metal-free g-carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy. The Journal of Biological Chemistry, 270, 7980-7987.
65. Freedman, S.J. et al. (1996) Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. The Journal of Biological Chemistry, 271, 16227-16236.
66. Huang, M. et al. (2003) Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nature Structural Biology, 10, 751-756.
67. Soriano-Garcia, M. et al. (1992) The Ca2{thorn} ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry, 31, 2554-2566.
68. Sunnerhagen, M. et al. (1995) Structure of the Ca2{thorn}-free Gla domain sheds light on membrane binding of blood coagulation proteins. Nature Structural Biology, 2, 504-509.
69. Sunnerhagen, M. et al. (1996) The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2{thorn} binding to the first EGF domain: a combined NMR-small angle X-ray scattering study. Biochemistry, 35, 11547-11559.
70. Gitel, S.N. et al. (1973) A polypeptide region of bovine prothrombin specific for binding to phospholipids. Proceedings of the National Academy of Sciences of the United States of America, 70, 1344-1348.
71. Nelsestuen, G.L., Broderius, M. and Martin, G. (1976) Role of g-carboxyglutamic acid: cation specificity of prothrombin and factor X-phospholipid binding. The Journal of Biological Chemistry, 251, 6886-6893.
72. Stenflo, J. and Suttie, J.W. (1977) Vitamin K-dependent formation of g-carboxyglutamic acid. Annual Review of Biochemistry, 46, 157-172.
73. London, F. and Walsh, P.N. (1996) The role of electrostatic interactions in the assembly of the factor X activating complex on both activated platelets and negatively-charged phospholipid vesicles. Biochemistry, 35, 12146-12154.
74. Oganesyan, V. et al. (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. The Journal of Biological Chemistry, 277, 24851-24854.
75. Regan, L.M. et al. (1997) The interaction between the endothelial cell protein C receptor and protein C is dictated by the g-carboxyglutamic acid domain of protein C. The Journal of Biological Chemistry, 272, 26279-26284.
76. Blostein, M.D. et al. (2003) The Gla domain of factor IXa binds to factor VIIIa in the tenase complex. The Journal of Biological Chemistry, 278, 31297-31302.
77. Larson, P.J. et al. (1996) Structural integrity of the g-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa. The Journal of Biological Chemistry, 271, 3869-3876.
78. Wolberg, A.S., Stafford, D.W. and Erie, D.A. (1997) Human factor IX binds to specific sites on the collagenous domain of collagen IV. The Journal of Biological Chemistry, 272, 16717-16720.
79. Blostein, M.D. et al. (2000) The Gla domain of human prothrombin has a binding site for factor Va. The Journal of Biological Chemistry, 275, 38120-38126.
80. Banner, D.W. et al. (1996) The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature, 380, 41-46.
81. Zhang, E., St Charles, R. and Tulinsky, A. (1999) Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. Journal of Molecular Biology, 285, 2089-2104.
82. Park, C.H. and Tulinsky, A. (1986) Threedimensional structure of the kringle sequence: structure of prothrombin fragment 1. Biochemistry, 25, 3977-3982.
83. Tulinsky, A. and Park, C.H. (1988) Structure of prothrombin fragment 1 and its relation to calcium binding, in Current Advances in Vitamin K Research, (ed J.W. Suttie), Elsevier Science Publishing Co., Inc., New York, pp. 295-304.
84. Seshadri, T.P.J. et al. (1991) Structure of bovine prothrombin fragment 1 refined at 2.25 Å resolution. Journal of Molecular Biology, 220, 481-494.
85. Brandstetter, H. et al. (1995) X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proceedings of the National Academy of Sciences of the United States of America, 92, 9796-800.
86. Huang, M., Furie, B.C. and Furie, B. (2004) Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. The Journal of Biological Chemistry, 279, 14338-14346.
87. Mizuno, H. et al. (1999) Crystal structure of coagulation factor IX-binding protein from Habu snake venom at 2.6 Å:implication of central loop swapping based on deletion in the linker region. Journal of Molecular Biology, 289, 103-112.
88. Shikamoto, Y. et al. (2003) Crystal structure of Mg2{thorn}- and Ca2{thorn}-bound Gla domain of factor IX complexed with binding protein. The Journal of Biological Chemistry, 278, 24090-24094.
89. Li, L. et al. (1997) Refinement of the NMR solution structure of the g-carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca2{thorn} positions determined by a genetic algorithm. Biochemistry, 36, 2132-2138.
90. Foster, D.C. et al. (1987) Propeptide of human protein C is necessary for g-carboxylation. Biochemistry, 26, 7003-7011.
91. Huber, P. et al. (1990) Identification of amino acids in the g-carboxylation recognition site on the propeptide of prothrombin. The Journal of Biological Chemistry, 265, 12467-12473.
92. Jorgensen, M.J. et al. (1987) Recognition site directing vitamin K-dependent g-carboxylation resides on the propeptide of factor IX. Cell, 48, 185-191.
93. Price, P.A., Fraser, J.D. and Metz-Virca, G. (1987) Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent g-carboxylase. Proceedings of the National Academy of Sciences of the United States of America, 84, 8335-8339.
94. Wise, R.J. et al. (1990) Expression of a human proprotein processing enzyme:correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. Proceedings of the National Academy of Sciences of the United States of America, 87, 9378-9382.
95. Bresnahan, P.A. et al. (1990) Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-b-NGF in vivo. The Journal of Cell Biology, 111, 2851-2859.
96. Stanton, C., Taylor, R. and Wallin, R. (1991) Processing of prothrombin in the secretory pathway. The Biochemical Journal, 277, 59-65.
97. Bentley, A.K. et al. (1986) Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. Cell, 45, 343-348.
98. Diuguid, D.L. et al. (1986) Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proceedings of the National Academy of Sciences of the United States of America, 83, 5803-5807.
99. Gandrille, S. et al. (1995) Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood, 85, 130-138.
100. Lind, B., Johnsen, A.H. and Thorsen, S. (1997) Naturally occurring Arg-1 to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C. Blood, 89, 2807-2816.
101. Reitsma, P.H. et al. (1995) Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thrombosis and Haemostasis, 73, 876-889.
102. Ware, J. et al. (1989) Factor IX San Dimas:substitution of glutamine for Arg-4 in the propeptide leads to incomplete g-carboxylation and altered phospholipid binding properties. The Journal of Biological Chemistry, 264, 11401-11406.
103. Stanley, T.B. et al. (1998) Role of the propeptide and g-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry, 37, 13262-13268.
104. Stenina, O. et al. (2001) Tethered processivity of the vitamin K-dependent carboxylase: factor IX is efficiently modified in a mechanism which distinguishes Gla's from Glu's and which accounts for comprehensive carboxylation in vivo. Biochemistry, 40, 10301-10309.
105. Berkner, K.L. (2008) Vitamin K-dependent carboxylation. Vitamins and Hormones, 78, 131-156.
106. Suttie, J.W. (1993) Synthesis of vitamin K-dependent proteins. The FASEB Journal, 7, 445-452.
107. Dowd, P. et al. (1995) The mechanism of action of vitamin K. Annual Review of Nutrition, 15, 419-440.
108. Davis, C.H. et al. (2007) A quantum chemical study of the mechanism of action of Vitamin K carboxylase (VKC) III. Intermediates and transition states. Journal of Molecular Graphics & Modelling, 26, 409-414.
109. Wajih, N. et al. (2004) The inhibitory effect of calumenin on the vitamin K-dependent g-carboxylation system: characterization of the system in normal and warfarinresistant rats. The Journal of Biological Chemistry, 279, 25276-25283.
110. Jin, D.-Y., Tie, J.-K. and Stafford, D.W. (2007) The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry, 46, 7279-7283.
111. Wallin, R., Wajih, N. and Hutson, S.M. (2008) VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors. Vitamins and Hormones, 78, 227-246.
112. Zimmermann, A. and Matschiner, J.T. (1974) Biochemical basis of hereditary resistance to warfarin in the rat. Biochemical Pharmacology, 23, 1033-1040.
113. Fasco, M.J. et al. (1983) Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes. Biochemistry, 22, 5655-5660.
114. Wajih, N. et al. (2005) Engineering of a recombinant vitamin K-dependent g-carboxylation system with enhanced g-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. The Journal of Biological Chemistry, 280, 10540-10547.
115. Wajih, N., Hutson, S.M. and Wallin, R. (2007) Disulfide dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum: a protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin k1 2,3-epoxide reduction. The Journal of Biological Chemistry, 282, 2626-2635.
116. Thijssen, H.H.W., Baars, L.G.M. and Vervoort-Peters, H.T.M. (1988) Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. British Journal of Pharmacology, 95, 675-682.
117. Furie, B. (2000) Oral anticoagulant therapy, in Hematology: Basic Principles and Practice (eds R. Hoffman, E.J.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein and P. McGlave), Churchill Livingstone, New York, pp. 2040-2046.
118. Suttie, J.W. (1987) The biochemical basis of warfarin therapy, in The New Dimensions ofWarfarin Prophylaxis (eds S. Wessler, C.G. Becker and Y. Nemerson), Plenum Press, New York, pp. 3-16.
119. Silverman, R.B., Mukharji, I. and Nandi, D.L. (1988) Solubilization, partial purification, mechanism, and inactivation of vitamin K epoxide reductase, in Current Advances in Vitamin K Research (eds J.W. Suttie), Elsevier Science Publishing Co., Inc., New York, pp. 65-74.
120. Stanton, C. and Wallin, R. (1992) Processing and trafficking of clotting factor X in the secretory pathway: effects of warfarin. The Biochemical Journal, 284, 25-31.
121. Shearer, M.J., Bach, A. and Kohlmeier, M. (1996) Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. The Journal of Nutrition, 126 (Suppl. 4), 1181S-1186.
122. Ferland, G. (1998) The vitamin K-dependent proteins: an update. Nutrition Reviews, 56, 223-230.
123. Stenberg, L.M. et al. (2001) A functional prothrombin gene product is synthesized by human kidney cells. Biochemical and Biophysical Research Communications, 280, 1036-1041.
124. Stenberg, L.M. et al. (2001) Synthesis of g-carboxylated polypeptides by a-cells of the pancreatic islets. Biochemical and Biophysical Research Communications, 283, 454-459.
125. Malm, J. et al. (1994) Vitamin Kdependent protein S in Leydig cells of human testis. The Biochemical Journal, 302, 845-850.
126. Ishimoto, Y. and Nakano, T. (2000) Release of a product of growth arrestspecific gene 6 from rat platelets. FEBS Letters, 466, 197-199.
127. Ducy, P. et al. (1996) Increased bone formation in osteolcalcin-deficient mice. Nature, 382, 448-452.
128. Reza, M.A. et al. (2006) Molecular evolution caught in action: gene duplication and evolution of molecular isoforms of prothrombin activators in Pseudonaja textilis (brown snake). Journal of Thrombosis and Haemostasis, 4, 1346-1353.
129. Kurachi, K. and Davie, E.W. (1982) Isolation and characterization of a cDNA coding for human factor IX. Proceedings of the National Academy of Sciences of the United States of America, 79, 6461-6464.
130. High, K.A. and Roberts, H.R. (1995) Factor IX, in Molecular Basis of Thrombosis and Hemostasis (eds K.A. High and H.R. Roberts), Marcel Dekker, Inc., New York, pp. 215-237.
131. Bajaj, S.P. and Birktoft, J.J. (1993) Human factor IX and factor IXa. Methods in Enzymology, 222, 96-128.
132. Gailani, D. et al. (2001) Model for a factor IX activation complex on blood platelets:dimeric conformation of factor XIa is essential. Blood, 97, 3117-3122.
133. Lenting, P.J. et al. (1995) Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. The Journal of Biological Chemistry, 270, 14884-14890.
134. Agarwala, K.L. et al. (1994) Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169. Biochemistry, 33, 5167-5171.
135. Di Scipio, R.G., Kurachi, K. and Davie, E.W. (1978) Activation of human factor IX (Christmas factor). The Journal of Clinical Investigation, 61, 1528-1538.
136. Giannelli, F. et al. (1998) Haemophilia B:database of point mutations and short additions and deletions-eighth edition. Nucleic Acids Research, 26, 265-268.
137. Sommer, S.S., Scaringe, W.A. and Hill, K.A. (2001) Human germline mutation in the factor IX gene. Mutation Research, 487, 1-17.
138. Edwards, J. and Kirkby, N. (1999) Recombinant coagulation factor IX (BeneFIX-), in Biopharmaceuticals, an Industrial Perspective (eds G.Walsh and B. Murphy), Kluwer Academic Publishers, The Netherlands, pp. 73-108.
139. Harrison, S. et al. (1998) The manufacturing process for recombinant factor IX. Seminars in Hematology, 35, 4-10.
140. Bond, M. et al. (1998) Biochemical characterization of recombinant factor IX. Seminars in Hematology, 35 (Suppl. 2), 11-17.
141. Broze, G.J. Jr (1992) The role of tissue factor pathway inhibitor in a revised coagulation cascade. Seminars in Hematology, 29, 159-169.
142. Østerud, B. (1997) Tissue factor: a complex biological role. Thrombosis and Haemostasis, 78, 755-758.
143. Giesen, P.L. et al. (1999) Blood-borne tissue factor: another view of thrombosis. Proceedings of the National Academy of Sciences of the United States of America, 96, 2311-2315.
144. Thim, L. et al. (1988) Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry, 27, 7785-7793.
145. Erhardtsen, E. et al. (2006) Recombinant factor VIIa, in Directory of Therapeutic Enzymes (eds B.M. McGrath and G. Walsh), CRC Press, Boca Raton, Florida, pp. 189-207.
146. Butenas, S. and Mann, K.G. (1996) Kinetics of human factor VII activation. Biochemistry, 35, 1904-1910.
147. Dahlbäck, B. and Villoutreix, B.O. (2005) The anticoagulant protein C pathway. FEBS Letters, 579, 3310-3316.
148. Fay, P.J., Smudzin, T.M. and Walker, F.J. (1991) Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. The Journal of Biological Chemistry, 266, 20139-20145.
149. Kalafatis, M., Rand, M.D. and Mann, K.G. (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. The Journal of Biological Chemistry, 269, 31869-31880.
150. Comp, P.C. and Esmon, C.T. (1981) Generation of fibrinolytic activity by infusion of activated protein C into dogs. The Journal of Clinical Investigation, 68, 1221-1228.
151. Esmon, C.T., Taylor, F.B. Jr and Snow, T.R. (1991) Inflammation and coagulation:linked processes potentially regulated through a common pathway mediated by protein C. Thrombosis and Haemostasis, 66, 160-165.
152. Snow, T.R. et al. (1991) Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation, 84, 293-299.
153. Foster, D. and Davie, E.W. (1984) Characterization of a cDNA coding for human protein C. Proceedings of the National Academy of Sciences of the United States of America, 81, 4766-47670.
154. Plutzky, J. et al. (1986) Evolution and organization of the human protein C gene. Proceedings of the National Academy of Sciences of the United States of America, 83, 546-550.
155. Stenflo, J. (1976) A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. The Journal of Biological Chemistry, 251, 355-363.
156. Marlar, R.A. (1985) Plasma single chain protein C is functionally similar to the two chain form of plasma protein C. Thrombosis and Haemostasis, 54, 216.
157. Greffe, B.S., Manco-Johnson, M.J. and Marlar, R.A. (1989) Molecular forms of human protein C: comparison and distribution in human adult plasma. Thrombosis and Haemostasis, 62, 902-905.
158. Esmon, C.T. (1984) Protein C. Progress in Hemostasis and Thrombosis, 7, 25-54.
159. Kisiel, W. (1979) Human plasma protein C: isolation, characterization, and mechanism of activation by a-thrombin. The Journal of Clinical Investigation, 64, 761-769.
160. Oppenheimer, C. and Wydro, R. (1988) Cellular processing of vitamin K-dependent proteins, in Current Advances in Vitamin K Research, (ed J.W. Suttie), Elsevier Science Publishing Co., Inc., New York, pp. 165-171.
161. Foster, D.C. et al. (1990) Endoproteolytic processing of the dibasic cleavage site in the human protein C precursor in transfected mammalian cells: effects of sequence alterations on efficiency of cleavage. Biochemistry, 29, 347-354.
162. Yan, S.C.B., Grinnell, B.W. and Wold, F. (1989) Post-translational modifications of proteins: some problems left to solve. Trends in Biochemical Sciences, 14, 264-268.
163. Laterre, P.F. (2007) Clinical trials in severe sepsis with drotrecogin alfa (activated). Critical Care (London, England), 11, S5.
164. O'Brien, L.A., Gupta, A. and Grinnell, B.W. (2006) Activated protein C and sepsis. Frontiers in Bioscience: a Journal and Virtual Library, 11, 676-698.
165. Rivard, G.E. et al. (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. The Journal of Pediatrics, 126, 646-652.
166. Grinnell, B.W., Yan, S.B. and Macias, W.L. (2006) Activated protein C, in Directory of Therapeutic Enzymes, (eds B.M. McGrath and G. Walsh), CRC Press, Boca Raton, Florida, pp. 69-95.
167. Mann, K.G. et al. (1990) Surfacedependent reactions of the vitamin K-dependent enzyme complexes. Blood, 76, 1-16.
168. Jackson, C.M. (1994) Physiology and biochemistry of prothrombin, in Haemostasis and Thrombosis (eds A.L. Bloom, C.D. Forbes, D.P. Thomas and E.G.D. Tuddenham), Churchill Livingstone, Edinburgh, pp. 397-438.
169. Chapman, W.C. et al. (2007) A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. Journal of the American College of Surgeons, 205, 256-265.
170. Craig, A.G. (2000) The characterization of conotoxins. Journal of Toxicology. Toxin Reviews, 19, 53-93.
171. Sharpe, I.A. et al. (2001) Two new classes of conopeptides inhibit the a1- adrenoceptor and noradrenaline transporter. Nature Neuroscience, 4, 902-907.
172. Santos, A.D. et al. (2004) The A-superfamily of conotoxins: structural and functional divergence. The Journal of Biological Chemistry, 279, 17596-17606.
173. Terlau, H. and Olivera, B.M. (2004) Conus venoms: a rich source of novel ion channel-targeted peptides. Physiological Reviews, 84, 41-68.
174. Armishaw, C.J. and Alewood, P.F. (2005) Conotoxins as research tools and drug leads. Current Protein & Peptide Science, 6, 221-240.
175. Grant, M.A., Shanmugasundaram, K. and Rigby, A.C. (2007) Conotoxin therapeutics: a pipeline for success? Expert Opinion Drug Discovery, 2, 453-468.
176. Olivera, B.M. and Teichert, R.W. (2007) Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery. Molecular Interventions, 7, 251-260.
177. Sharp, D. (2005) Novel pain relief via marine snails. Lancet, 366, 439-440.
178. Woodward, S.R. et al. (1990) Constant and hypervariable regions in conotoxin propeptides. The EMBO Journal, 9, 1015-1020.
179. Kauferstein, S. et al. (2003) A novel conotoxin inhibiting vertebrate voltage-sensitive potassium channels. Toxicon, 42, 43-52.
180. Stanley, T.B. et al. (1997) Identification of a vitamin K-dependent carboxylase in the venom duct of a Conus snail. FEBS Letters, 407, 85-88.
181. Prorok, M. et al. (1996) Calcium binding properties of synthetic g-carboxyglutamic acid-containing marine cone snail ?sleeper? peptides, conantokin-G and conantokin-T. Biochemistry, 35, 16528-16534.
182. Lang, P.M. et al. (2005) A Conus peptide blocks nicotinic receptors of unmyelinated axons in human nerves. Neuroreport, 16, 479-483.
183. Sandall, D.W. et al. (2003) A novel a-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry, 42, 6904-6911.
184. Berkner, K.L. (1993) Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. Methods in Enzymology, 222, 450-477.
185. Chaing, S. et al. (1994) Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood, 83, 3524-3535.
186. Kaufman, R.J. et al. (1986) Expression, purification, and characterization of recombinant g-carboxylated factor IX synthesized in Chinese hamster ovary cells. The Journal of Biological Chemistry, 261, 9622-9628.
187. Toomey, J.R., Smith, K.J. and Stafford, D.W. (1991) Localization of the human tissue factor recognition determinant of human factor VIIa. The Journal of Biological Chemistry, 266, 19198-19202.
188. Yan, S.C.B. et al. (1990) Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Bio/Technology, 8, 655-661.
189. Van Cott, K.E. et al. (1999) Transgenic pigs as bioreactors: a comparison of gamma-carboxylation of glutamic acid in recombinant human protein C and factor IX by themammary gland. Genet Analysis, 15, 155-160.
190. Rehemtulla, A. et al. (1993) In vitro and in vivo functional characterization of bovine vitamin K-dependent g-carboxylase expressed in Chinese hamster ovary cells. Proceedings of the National Academy of Sciences of the United States of America, 90, 4611-4615.
191. Wu, S.-M. et al. (1991) Cloning and expression of the cDNA for human g-glutamyl carboxylase. Science, 254, 1634-1636.
192. Hallgren, K.W. et al. (2002) Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX:implications for the release of vitamin K-dependent proteins. Biochemistry, 41, 15045-15055.
193. Sun, Y.-M. et al. (2005) Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X. Blood, 106, 3811-3815.
194. Wajih, N. et al. (2005) Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxidereducing enzyme of the vitamin K cycle. The Journal of Biological Chemistry, 280, 31603-31607.
195. Berkner, K.L. (2005) The vitamin K-dependent carboxylase. Annual Review of Nutrition, 25, 127-149.
196. Hallgren, K.W. et al. (2006) r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step. Biochemistry, 45, 5587-5598.
197. Wajih, N., Hutson, S.M. and Wallin, R. (2006) siRNA silencing of calumenin enhances functional factor IX production. Blood, 108, 3757-3760.
198. Wajih, N., Owen, J. and Wallin, R. (2008) Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection. Thrombosis Research, 122, 405-410.
199. Wallin, R. et al. (2001) A molecular mechanism for genetic warfarin resistance in the rat. The FASEB Journal, 15, 2542-2544.
200. Handford, P.A., Winship, P.R. and Brownlee, G.G. (1991) Protein engineering of the propeptide of human factor IX. Protein Engineering, 4, 319-323.
201. Stanley, T.B. et al. (1999) The propeptides of the vitamin K-dependent proteins possess different affinities for the vitamin K-dependent carboxylase. The Journal of Biological Chemistry, 274, 16940-16944.
202. Camire, R.M. et al. (2000) Enhanced g-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry, 39, 14322-14329.
203. Rudolph, A.E. et al. (1997) Expression, purification, and characterization of recombinant human factor X. Protein Expression and Purification, 10, 373-378.
204. Jackson, C.M., Johnson, T.F. and Hanahan, D.J. (1968) Studies on bovine factor X. I. Large-scale purification of the bovine plasma protein possessing factorX activity. Biochemistry, 7, 4492-4505.
205. Di Scipio, R.G. et al. (1977) A comparison of human prothrombin, factor IX (Christmas factor), factorX(Stuart factor), and protein S. Biochemistry, 16, 698-706.
206. Yan, S.B. (1996) Review of conformationspecific affinity purification methods for plasma vitamin K-dependent proteins. Journal of Molecular Recognition, 9, 211-218.
207. Brown, M.A. et al. (2000) Identification and purification of vitamin K-dependent proteins and peptides with monoclonal antibodies specific for g-carboxyglutamyl (Gla) residues. The Journal of Biological Chemistry, 275, 19795-19802.
208. Cairns, J.R., Williamson, M.K. and Price, P.A. (1991) Direct identification of g-carboxyglutamic acid in the sequencing of vitamin K-dependent proteins. Analytical Biochemistry, 199, 93-97.
209. Jie, K.-S.G., Gijsbers, B.L.M.G. and Vermeer, C. (1995) A specific colorimetric staining method for g-carboxyglutamic acid-containing proteins in polyacrylamide gels. Analytical Biochemistry, 224, 163-165.
210. Hauschka, P.V. (1979) Specific tritium labeling of g-carboxyglutamic acid in proteins. Biochemistry, 18, 4992-4999.
211. Kuwada, M. and Katayama, K. (1983) An improved method for the determination of g-carboxyglutamic acid in proteins, bone, and urine. Analytical Biochemistry, 131, 173-179.
212. Vo, H.C. et al. (1999) Undercarboxylation of recombinant prothrombin revealed by analysis of g-carboxyglutamic acid using capillary electrophoresis and laserinduced fluorescence. FEBS Letters, 445, 256-260.
213. Castellino, F.J., Ploplis, V.A. and Zhang, L. (2008) g-Glutamate and bhyydroxyaspartate in proteins. Methods in Molecular Biology (Clifton, NJ), 446, 85-94.
214. Carr, S.A., Hauschka, P.V. and Biemann, K. (1981) Gas chromatographic mass spectrometric sequence determination of osteocalcin, a g-carboxyglutamic acid-containing protein from chicken bone. The Journal of Biological Chemistry, 256, 9944-9950.
215. Kalume, D.E. et al. (2000) Structure determination of two conotoxins from Conus textile by a combination of matrixassisted laser desorption/ionization timeof- flight and electrospray ionization mass spectrometry and biochemical methods. Journal ofMass Spectrometry, 35, 145-156.
216. Kelleher, N.L. et al. (1999) Localization of labile posttranslational modifications by electron capture dissociation: the case of g-carboxyglutamic acid. Analytical Chemistry, 71, 4250-4253.
217. Deerfield, D.W. II et al. (1987) Mg(II) binding by bovine prothrombin fragment 1 via equilibrium dialysis and the relative roles of Mg(II) and Ca(II) in blood coagulation. The Journal of Biological Chemistry, 262, 4017-4023.
218. Sabharwal, A.K. et al. (1995) High affinity Ca2{thorn}-binding site in the serine protease domain of human factor VIIa and its role in tissue factor binding and development of catalytic activity. The Journal of Biological Chemistry, 270, 15523-15530.
219. Zapata, G.A. et al. (1988) Chemical modification of bovine prothrombin fragment 1 in the presence of Tb3{thorn} ions:sequence studies on 3-g-MGlu-fragment 1. The Journal of Biological Chemistry, 263, 8150-8156.
220. Jackson, C.M. (1988) Calcium ion binding to g-carboxyglutamic acid-containing proteins from the blood clotting system:what we still don't understand, in Current Advances in Vitamin K Research, (ed J.W. Suttie), Elsevier Science Publishing Co., Inc., New York, pp. 305-324.
221. Colpitts, T.L. and Castellino, F.J. (1994) Calcium and phospholipid binding properties of synthetic g-carboxyglutamic acid-containing peptides with sequence counterparts in human protein C. Biochemistry, 33, 3501-3508.
222. Stenflo, J. (1970) Dicumarol-induced prothrombin in bovine plasma. Acta Chemica Scandinavica, 24, 3762-3763.
223. Björk, I. and Stenflo, J. (1973) A conformational study of normal and dicoumarol-induced prothrombin. FEBS Letters, 32, 343-346.
224. Marsh, H.C. et al. (1979) Magnesium and calcium ion binding to bovine prothrombin fragment 1: a circular dichroism, fluorescence, and 43Ca2{thorn} and 25Mg2{thorn} nuclear magnetic resonance study. The Journal of Biological Chemistry, 254, 10268-10275.
225. Häfner, A. et al. (2000) Calcium-induced conformational change in fragment 1-86 of factor X. Biopolymers, 57, 226-234.
226. Hof, M. (1998) Picosecond tryptophan fluorescence of membrane-bound prothrombin fragment 1. Biochimica et Biophysica Acta, 1388, 143-153.
227. Nelsestuen, G.L. (1976) Role of g-carboxyglutamic acid: an unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. The Journal of Biological Chemistry, 251, 5648-5656.
228. Bajaj, S.P., Nowak, T. and Castellino, F.J. (1976) Interaction of manganese with bovine prothrombin and its thrombinmediated cleavage products. The Journal of Biological Chemistry, 251, 6294-6299.
229. Furie, B.C., Blumenstein, M. and Furie, B. (1979) Metal binding sites of a g-carboxyglutamic acid-rich fragment of bovine prothrombin. The Journal of Biological Chemistry, 254, 12521-12530.
230. Lentz, B.R., Zhou, C.-M. and Wu, J.R. (1994) Phosphatidylserine-containing membranes alter the thermal stability of prothrombin's catalytic domain:a differential scanning calorimetric study. Biochemistry, 33, 5460-5468.
231. Vysotchin, A., Medved, L.V. and Ingham, K.C. (1993) Domain structure and domain-domain interactions in human coagulation factor IX. The Journal of Biological Chemistry, 268, 8436-8446.
232. Wu, J.R. and Lentz, B.R. (1991) Fourier transform infrared spectroscopic study of Ca2{thorn} and membrane-induced secondary structural changes in bovine prothrombin and prothrombin fragment 1. Biophysical Journal, 60, 70-80.
233. Jacobs, M. et al. (1994) Membrane binding properties of the factor IX g-carboxyglutamic acid-rich domain prepared by chemical synthesis. The Journal of Biological Chemistry, 269, 25494-25501.
234. Falls, L.A. et al. (2001) The w-loop region of the human prothrombin g-carboxyglutamic acid domain penetrates anionic phospholipid membranes. The Journal of Biological Chemistry, 276, 23895-23902.
235. Zhang, L. and Castellino, F.J. (1993) The contributions of individual g-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein C to acidic phospholipid vesicles. The Journal of Biological Chemistry, 268, 12040-12045.
236. Suttie, J.W., Canfield, L.M. and Shah, D.V. (1980) Microsomal vitamin K-dependent carboxylase. Methods in Enzymolgy, 67, 180-185.
237. Traverso, H.P., Hauschka, P.V. and Gallop, P.M. (1980) Vitamin K-dependent carboxylation in microsomal preparations derived from cultured kidney cells, chick embryo fibroblasts, and pancreas, in Vitamin K Metabolism and Vitamin K-dependent Proteins (ed J.W. Suttie), University Park Press, Baltimore, Maryland, pp. 311-314.
238. Vermeer, C. (1990) g-Carboxyglutamatecontaining proteins and the vitamin K-dependent carboxylase. The Biochemical Journal, 266, 625-636.
239. Ulrich, M.M.W. et al. (1988) Vitamin K-dependent carboxylation: a synthetic peptide based upon the g-carboxylation recognition site sequence of the prothrombin propeptide is an active substrate for the carboxylase in vitro. The Journal of Biological Chemistry, 263, 9697-9702.
240. Brodsky, B. and Shah, N.K. (1995) Protein motifs. 8. The triple-helix motif in proteins. The FASEB Journal, 9, 1537-1546.
241. Brennan, S.O. et al. (1993) Posttranslational modification of b141 Leu associated with the b75(E19) Leu!Pro mutation in Hb Atlanta. Hemoglobin, 17, 1-7.
242. Aguilar, M.B. et al. (2005) A novel conotoxin from Conus delessertii with posttranslationally modified lysine residues. Biochemistry, 44, 11130-11136.
243. Buczek, O., Bulaj, G. and Olivera, B.M. (2005) Conotoxins and the posttranslational modification of secreted gene products. Cellular and Molecular Life Sciences, 62, 3067-3079.
244. Franco, A. et al. (2006) Hyperhydroxylation: a new strategy for neuronal targeting by venomous marine molluscs, in Progress in Molecular and Subcellular Biology, Subseries Marine Molecular Biotechnology: Molluscs, (eds G. Cimino and M. Gavagnin), Springer-Verlag, Berlin, pp. 83-103.
245. Pisarewicz, K. et al. (2005) Polypeptide chains containing D-g-hydroxyvaline. Journal of the American Chemical Society, 127, 6207-6215.
246. Stone, B.L. and Gray, W.R. (1982) Occurrence of hydroxyproline in a toxin from the marine snail Conus geographus. Archives of Biochemistry and Biophysics, 216, 765-767.
247. Luo, C. et al. (1992) Recombinant human complement subcomponent C1s lacking b-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex. Biochemistry, 31, 4254-4262.
248. Przysiecki, C.T. et al. (1987) Occurrence of b-hydroxylated asparagine residues in non-vitamin K-dependent proteins containing epidermal growth factor-like domains. Proceedings of the National Academy of Sciences of the United States of America, 84, 7856-7860.
249. Stenflo, J. et al. (1988) b-Hydroxyaspartic acid or b-hydroxyasparagine in bovine low density lipoprotein receptor and in bovine thrombomodulin. The Journal of Biological Chemistry, 263, 21-24.
250. Valcarce, C., Björk, I. and Stenflo, J. (1999) The epidermal growth factor precursor:a calcium-binding, b-hydroxyasparagine containing modular protein present on the surface of platelets. European Journal of Biochemistry, 260, 200-207.
251. Drakenberg, T. et al. (1983) b-hydroxyaspartic acid in vitamin K-dependent protein C. Proceedings of the National Academy of Sciences of the United States of America, 80, 1802-1806.
252. Fernlund, P. and Stenflo, J. (1983) b-hydroxyaspartic acid in vitamin K-dependent proteins. The Journal of Biological Chemistry, 258, 12509-12512.
253. McMullen, B.A. et al. (1983) Complete amino acid sequence of the light chain of human blood coagulation factor X:evidence for identification of residue 63 as b-hydroxyaspartic acid. Biochemistry, 22, 2875-2884.
254. Stenflo, J., Lundwall, Å. and Dahlbäck, B. (1987) b-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proceedings of the National Academy of Sciences of the United States of America, 84, 368-372.
255. Sugo, T., Fernlund, P. and Stenflo, J. (1984) erythro-b-Hydroxyaspartic acid in bovine factor IX and factor X. FEBS Letters, 165, 102-106.
256. White, G.C. II et al. (1998) Mammalian recombinant coagulation proteins:structure and function. Transfusion Science, 19, 177-189.
257. Boswell, E.J., Kurinawan, N.D. and Downing, A.K. (2004) Calcium-binding EGF-like domains, in Handbook of Metalloproteins, (eds A. Messerschmidt, W. Bode and M. Cygler), John Wiley & Sons, Ltd., Chichester, England, pp. 1-18.
258. Rao, Z. et al. (1995) The structure of a Ca2{thorn}-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell, 82, 131-141.
259. Selander, M. et al. (1990) 1H NMR assignment and secondary structure of the Ca2{thorn}-free form of the amino-terminal epidermal growth factor like domain in coagulation factor X. Biochemistry, 29, 8111-8118.
260. Selander-Sunnerhagen, M. et al. (1992) How an epidermal growth factor (EGF)-like domain binds calcium: high resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X. The Journal of Biological Chemistry, 267, 19642-19649.
261. Muranyi, A. et al. (1998) Solution structure of the N-terminal EGF-like domain from human factor VII. Biochemistry, 37, 10605-10615.
262. Stenflo, J., Stenberg, Y. and Muranyi, A. (2000) Calcium-binding EGF-like modules in coagulation proteinases:function of the calcium ion in module interactions. Biochimica et Biophysica Acta (Protein Structure and Molecular Enzymology), 1477, 51-63.
263. Morita, T. and Kisiel, W. (1985) Calcium binding to a human factor IXa derivative lacking g-carboxyglutamic acid: evidence for two high-affinity sites that do not involve b-hydroxyaspartic acid. Biochemical and Biophysical Research Communications, 130, 841-847.
264. Selander-Sunnerhagen, M. et al. (1993) The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. The Journal of Biological Chemistry, 268, 23339-23344.
265. Davis, L.M. et al. (1987) Factor IXAlabama:a point mutation in a clotting protein results in hemophilia B. Blood, 69, 140-143.
266. Green, P.M. et al. (1989) Molecular pathology of haemophilia B. The EMBO Journal, 8, 1067-1072.
267. Green, P.M. et al. (1991) Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity. British Journal of Haematology, 78, 390-397.
268. Kainulainen, K. et al. (1994) Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nature Genetics, 6, 64-69.
269. Lin, S.W. and Shen, M.C. (1991) Characterization of genetic defects of hemophilia B of Chinese origin. Thrombosis andHaemostasis, 66, 459-463.
270. Liu, J.-Z. et al. (2000) The human factor IX gene as germline mutagen test: samples from Mainland China have the putatively endogenous pattern of mutation. Human Mutation, 16, 31-36.
271. Lozier, J.N. et al. (1990) Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood, 75, 1097-1104.
272. Tartary, M. et al. (1993) Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis. British Journal of Haematology, 84, 662-669.
273. Winship, P.R. and Dragon, A.C. (1991) Identification of haemophilia B patients with mutations in the two calcium binding domains of factor IX: importance of a b-OH Asp 64!Asn change. British Journal of Haematology, 77, 102-109.
274. Derian, C.K. et al. (1989) Inhibitors of 2-ketoglutarate-dependent dioxygenases block aspartyl b-hydroxylation of recombinant human factor IX in several mammalian expression systems. The Journal of Biological Chemistry, 264, 6615-6618.
275. Nelson, R.M. et al. (1991) b-Hydroxyaspartic acid and b-hydroxyasparagine residues in recombinant human protein S are not required for anticoagulant cofactor activity or for binding to C4b-binding protein. The Journal of Biological Chemistry, 266, 20586-20589.
276. Harris, R.J., Ling, V.T., Spellman, M.W. (1992) O-linked fucose is present in the first epidermal growth factor domain of factor XII but not protein C. The Journal of Biological Chemistry, 267, 5102-5107.
277. Dinchuk, J.E. et al. (2002) Absence of post-translational aspartyl b-Texthydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. The Journal of Biological Chemistry, 277, 12970-12977.
278. Lavaissiere, L. et al. (1996) Overexpression of human aspartyl(asparaginyl)bhydroxylase in hepatocellular carcinoma and cholangiocarcinoma. The Journal of Clinical Investigation, 98, 1313-1323.
279. Handford, P.A. et al. (1991) Key residues involved in calcium-binding motifs in EGF-like domains. Nature, 351, 164-167.
280. Gronke, R.S. et al. (1989) Aspartyl b-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proceedings of the National Academy of Sciences of the United States of America, 86, 3609-3613.
281. Stenflo, J. et al. (1989) Hydroxylation of aspartic acid in domains homologous to the epidermal growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 86, 444-447.
282. Jia, S. et al. (1992) cDNA cloning and expression of bovine aspartyl (asparaginyl) b-hydroxylase. The Journal of Biological Chemistry, 267, 14322-14327.
283. Korioth, F., Gieffers, C., Frey, J. (1994) Cloning and characterization of the human gene encoding aspartyl b-hydroxylase. Gene, 150, 395-399.
284. McNeill, L.A. et al. (2002) Hypoxiainducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the b-carbon of asparagine-803. The Biochemical Journal, 367, 571-575.
285. Kivirikko, K.I. and Pihlajaniemi, T. (1998) Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Advances in Enzymology and Related Areas of Molecular Biology, 72, 325-398.
286. Astermark, J. et al. (1991) Structural requirements for Ca2{thorn} binding to the g-carboxyglutamic acid and epidermal growth factor-like regions of factor IX:studies using intact domains isolated from controlled proteolytic digests of bovine factor IX. The Journal of Biological Chemistry, 266, 2430-2437.
287. Persson, K.E.M. et al. (1998) Calcium binding to the first EGF-like module of human factor IX in a recombinant fragment containing residues 1-85:mutations V46E and Q50E each manifest a negligible increase in calcium affinity. FEBS Letters, 421, 100-104.
288. Lenting, P.J. et al. (1996) Ca2{thorn} binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. The Journal of Biological Chemistry, 271, 25332-25337.
289. Rees, D.J. et al. (1988) The role of b-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX. The EMBO Journal, 7, 2053-2061.
290. Öhlin, A.-K., Linse, S., Stenflo, J. (1988) Calcium binding to the epidermal growth factor homology region of bovine protein C. The Journal of Biological Chemistry, 263, 7411-7417.
291. Mather, T. et al. (1996) The 2.8Å crystal structure of Gla-domainless activated protein C. The EMBO Journal, 15, 6822-6831.
292. Öhlin, A.-K. et al. (1988) b-Hydroxyaspartic acid in the first epidermal growth factor-like domain of protein C: its role in Ca2{thorn} binding and biological activity. The Journal of Biological Chemistry, 263, 19240-19248.
293. Gerlitz, B. et al. (1990) Effect of mutation of Asp71 on human protein C activation and function. Journal of Cellular Biochemistry, 44, 201.
294. Geng, J.P., Cheng, C.H. and Castellino, F.J. (1996) Functional consequences of mutations in amino acid residues that stabilize calcium binding to the first epidermal growth factor homology domain of human protein C. Thrombosis andHaemostasis, 76, 720-728.
295. Cheng, C.H., Geng, J.P. and Castellino, F.J. (1997) The functions of the first epidermal growth factor homology region of human protein C as revealed by a charge-to-alanine scanning mutagenesis investigation. Biological Chemistry, 378, 1491-500.
296. Martinez, A. (2007) Marine-derived drugs in neurology. Current Opinion in Investigational Drugs, 8, 525-530.
297. Nielsen, C.K. et al. (2005) Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain, 118, 112-124.
298. Obata, H., Conklin, D. and Eisenach, J.C. (2005) Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain, 113, 271-276.
299. Sharpe, I.A. et al. (2003) Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA: site of action, Na{thorn} dependence, and structure-activity relationship. The Journal of Biological Chemistry, 278, 40317-40323.
300. Nilsson, K.P. et al. (2005) Solution structure of c-conopeptide MrIA, a modulator of the human norepinephrine transporter. Biopolymers, 80, 815-823.
301. Zhang, J.-H. et al. (1999) Development of a carbon dioxide-capture assay in microtiter plate for aspartyl-betahydroxylase. Analytical Biochemistry, 271, 137-142.
302. Spitzer, S.G. et al. (1990) Factor IXHollywood: substitution of Pro55 by Ala in the first epidermal growth factor-like domain. Blood, 76, 1530-1537.
303. Denton, P.H. et al. (1988) Hemophilia B Durham: a mutation in the first EGF-like domain of factor IX that is characterized by polymerase chain reaction. Blood, 72, 1407-1411